



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/743,557	12/22/2003	Khalid K. Sadozai	0103343.00128US1	5063
23483	7590	04/16/2009		
WILMERHALE/BOSTON			EXAMINER	
60 STATE STREET			BROWN, COURTNEY A	
BOSTON, MA 02109				
		ART UNIT	PAPER NUMBER	
		1616		
		NOTIFICATION DATE	DELIVERY MODE	
		04/16/2009	ELECTRONIC	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

michael.mathewson@wilmerhale.com  
teresa.carvalho@wilmerhale.com  
sharon.mathews@wilmerhale.com

### Office Action Summary

**Application No.**

10/743,557

**Applicant(s)**

SADOZAI ET AL.

**Examiner**

COURTNEY BROWN

**Art Unit**

1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 10 September 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-16 and 18-48 is/are pending in the application.
- 4a) Of the above claim(s) 1-10 and 23-48 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 11-16 and 18-22 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/888)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Acknowledgement of Receipt/Status of Claims***

This Office Action is in response to the amendment filed September 10, 2008. Claims **1-16 and 18-48** are pending in the application. Claim 17 has been canceled. Claim 11 has been amended. Claims 1-10 and 23-48 have been withdrawn as being directed to a non-elected invention. Claims **11-16 and 18-22** are being examined for patentability.

Applicant's arguments, see pages 12-20, filed September 10, 2008, with respect to the rejection(s) of claim(s) 11-22 under 35 USC 103 (a) have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection has been made below.

Rejections not reiterated from the previous Office Action are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of rejections and/or objections presently being applied to the instant application.

### ***Claim Objection(s)***

Claim **20** is objected to because of the following informalities: Line 4 of claim 20 has "; and" at the end of the claim. This appears to be a typographical error. Appropriate correction or explanation is required.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

**Claims 11-16 and 18-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Leshchiner et al. (US Patent 5,143,724) in combination with Fujita et al. (JP 2000230001 A) in view of Chasin et al. (US Patent 5,942,241) and Aeschlimann et al. (US Patent 7196180).**

***Applicant's Invention***

Applicant claims a method of augmenting tissue in a human in need comprising the use of a hyaluronic acid (HA) composition that includes cross-linked, water-insoluble hydrated hyaluronic acid gel particles. These particles have a preferred diameter between about 20  $\mu\text{m}$  to about 1000  $\mu\text{m}$  wherein the distribution of the said particles is a multimodal distribution. The cross linkage of said particle may be performed with different compounds such as an optionally substituted o-acyl isourea or N-acyl urea. The aforementioned composition may further comprise a local anesthetic, specifically, lidocaine HCl. Additionally, the claimed method comprises the administration of the hyaluronic acid composition by forceful needle injection into a human at the location needing tissue augmentation.

***Determination of the scope and the content of the prior art  
(MPEP 2141.01)***

Leshchiner et al. teach the application of biocompatible viscoelastic gel slurries comprising swollen polymeric gel particles uniformly distributed in a second phase (column 2, lines 59-65) for soft tissue augmentation wherein the basic properties

of the mixed gel slurries including: biocompatibility; controlled viscoelasticity and diffusion characteristics; easily controlled residence time at the site of implantation; and easy handling of the material allows its injection through a small diameter needle (column 9, lines 10-22). Leshchiner et al. teach the use of a variety of polymeric gels such as hyaluronan (i.e., hyaluronic acid and its biologically acceptable salts) for use in the aforementioned slurries (column 2, line 66 bridging to column 3, lines 1-5) wherein said polymeric gels can be made of polymers which have been insolubilized by crosslinking (column 3, lines 23-35). Leshchiner et al. teach that said viscoelastic gel mixtures may contain many other components such as various physiologically active substances, including drugs (column 7, lines 60-end). In Examples 1-4, Leshchiner et al. teach that the rheological properties of the aforementioned viscoelastic gel mixtures were evaluated with the Bohlin Rheometer System which is a computerized rheometer with controlled shear rate and which can operate in three modes: viscometry, oscillation and relaxation wherein measurements of viscoelastic properties at various frequencies characterize the balance between elastic (storage modulus  $G'$ ) and viscous (loss modulus  $G''$ ) properties (column 9, lines 32-end). In light of the fact that Leshchiner et al. teach the use of the Bohlin Rheometer System to measure the storage modulus  $G'$  and the other viscoelastic properties, it is the Examiner's position that the storage modulus  $G'$  and the kinematic viscosity of the instant composition can only be determined experimentally (claims 20-22 of the instant application).

Fujita et al. teach a medical material with an especially high biocompatibility which is produced by incorporating a gel formed from hyaluronic acid. Fujita et al. teach that said gel is crushed with a suitable crusher to an average particle size of 10 mm or smaller (preferably 10-5000 micrometers, see [0019]) and used for injection and then suspended in a concentration of 0.1-5 wt.% in an arbitrary solution, giving a gel slurry suitable for in-vivo decomposable medical materials and cosmetics (abstract). In reference to claim 18, wherein the instant invention requires that the a multimodal distribution, the specification discloses, on page 13, lines 3-7, that **“the resulting composition has an average diameter distribution that is different from the ground particles before sizing, for example, the average diameter distribution can be a multimodal average diameter distribution, e.g., a bimodal average diameter distribution when two average diameter fractions are selected for the composition. The properties of the multimodal composition are built from the properties of the individual average diameter fractions and their amounts in the composition.”** Therefore, it is the Examiner's position that if the instant composition has multiple average diameter fractions, it is taught by Fujita et al.

***Ascertainment of the difference between the prior art and the claims  
(MPEP 2141.02)***

The difference between the invention of the instant application and that of Fujita et al. and Leshchiner et al. is that the instant invention claims that the HA composition include lidocaine HCL as a bioactive agent as opposed to being silent. For this reason,

the teaching of Chasin et al. is joined. Chasin et al. teach the use of a local anesthetic such as lidocaine (see claim 8 of reference) that can be formulated in injectable microspheres in combination with at least one augmenting agent (column 10, lines 20-24). Chasin et al. also teach the use of hyaluronic acid as a preferred controlled release material (column 12, lines 43-56).

A final difference between the invention of the instant application and that of Fujita et al. and Leshchiner et al. is that the instant invention claims the use of a hyaluronic acid (HA) composition that is cross-linked with different compounds such as optionally substituted o-acyl isourea or N- acyl urea. For this reason, the teaching of Aeschlimann et al. is joined. Aeschlimann et al. teach introducing a functionalized side chain onto HA wherein the direct carbodiimide-mediated coupling of amines to the carboxyl group of HA in an aqueous environment, with EDC (1-ethyl-3-[3-dimethylaminopropyl] carbodimide), produces O-acyl isourea which is formed as a reactive intermediate that rearranges rapidly to a stable N-acyl urea (see column 12, line 48 bridging to column 13, lines 1-5).

***Finding of prima facie obviousness***

***Rationale and Motivation (MPEP 2142-2143)***

It would have been obvious to one of ordinary skill in the art at the time of the invention to combine the teachings of the cited references to arrive at a method of augmenting tissue in a human in need comprising the use of a cross-linked hyaluronic

acid (HA) composition. Leshchiner et al. teach a method of augmenting tissue using HA combined with an active agent. Chasin et al. teach the use of lidocaine HCl in augmenting procedures. Aeschlimann et al. teach crosslinking HA to produce the O-acyl and N-acyl urea derivatives. Fujita et al. teach the use of HA particles for uniform administration ([0007] of Fujita et al.). One would have been motivated to make this combination in order to receive the expected benefit of having a painless method of augmenting tissue due to the use of lidocaine HCl that produces uniform administration due to the use of the HA particles.

### ***Response to Arguments***

Applicant's arguments, filed September 10, 2008, with respect to the 103 rejection of claims 11, 13, 14, 17 and 19 under 35 U.S.C. 103(a) as being unpatentable over Zhao et al. (US Patent Application 2002/0049281 A1) in view of Prestwich et al. (European Patent Application 0416205 A2) have been considered but are moot in view of the new ground(s) of rejection.

Applicant's arguments, filed September 10, 2008, with respect to the 103 rejection of claims 11, 12, 13, 14, 17, 19, and 20-22 under 35 U.S.C. 103(a) as being unpatentable over Zhao et al. (US Patent Application 2002/0049281 A1) in view of Duranti (Dermatologic Surgery) and further in view of Lawin et al. (WO/9602209 A1) have been considered but are moot in view of the new ground(s) of rejection.

Applicant's arguments, filed September 10, 2008, with respect to the 103 rejection of claims 11, 13-19, and 20-22 under 35 U.S.C. 103(a) as being unpatentable over Zhao et al. (US Patent Application 2002/0049281 A1) in view of Chasin et al. (US

Patent 5,942,241) have been considered but are moot in view of the new ground(s) of rejection.

The claims remain rejected.

### ***Conclusion***

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public

PAIR. Status information for unpublished applications is available through Private PAIR Only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electron Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Courtney Brown, whose telephone number is 571-270-3284. The examiner can normally be reached on Monday-Friday from 8 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's Supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Courtney A. Brown  
Patent Examiner  
Technology Center 1600  
Group Art Unit 1616

/Mina Haghighatian/  
Primary Examiner, Art Unit 1616